Tjark Reblin
Tjark Reblin publishes mostly in Surgery, Endocrinology, Diabetes and Metabolism and Molecular Biology, on topics such as Lipoproteins and Cardiovascular Health, Cancer, Lipids, and Metabolism and Diabetes, Cardiovascular Risks, and Lipoproteins.
- World rank
- #3,331,150 of 7,710,434 ranked researchers
- Rank in Germany
- #166,089 of 364,343
- Works
- 25
- Citations
- 1.1k
- Citations per work
- 43.2
What does Tjark Reblin research?
Tjark Reblin's work is mostly in Medicine (43%), Biochemistry, Genetics and Molecular Biology (17%).
Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.
The fields and subfields, with their numbers
- Health Sciences1142.8%
- Medicine1142.8%
- Everything else1040.1%
- Life Sciences417.1%
- 1Surgery21% of their works
- 2Endocrinology, Diabetes and Metabolism10% of their works
- 3Molecular Biology10% of their works
- 4Cancer Research7% of their works
- 5Public Health, Environmental and Occupational Health6% of their works
- 6Pharmacology6% of their works
Research topics
- Lipoproteins and Cardiovascular Health
- Cancer, Lipids, and Metabolism
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Metabolism, Diabetes, and Cancer
- Diabetes Treatment and Management
- Inflammatory mediators and NSAID effects
- Pharmaceutical Quality and Counterfeiting
- Peroxisome Proliferator-Activated Receptors
Which keywords describe Tjark Reblin's research?
The keywords of their largest research topics: Statins, Cardiovascular Disease Prevention, Cholesterol-lowering, Cholesterol, Cancer, Diabetes, Obesity and Inflammation.
- Peroxisome Proliferator-Activated Receptors
- Type 2 Diabetes
- Prostaglandins
- Cyclooxygenase-2 Inhibitors
- Cardiovascular Outcomes
- Metabolic Syndrome
- Fatty Acid Synthase
- Inflammation
- Diabetes
- Cholesterol
- Cardiovascular Disease Prevention
- Statins
- Cholesterol-lowering
- Cancer
- Obesity
- Cardiovascular Disease
- Lipid Metabolism
- AMP-Activated Protein Kinase
- Counterfeit Drugs
- Metformin
- Substandard Medicines
- PPARs
Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.
All 22 words, with their numbers
- Statins162 topics
- Cardiovascular Disease Prevention121 topic
- Cholesterol-lowering121 topic
- Cholesterol82 topics
- Cancer72 topics
- Diabetes62 topics
- Obesity62 topics
- Inflammation52 topics
- Cardiovascular Disease41 topic
- Fatty Acid Synthase41 topic
- Lipid Metabolism41 topic
- Metabolic Syndrome41 topic
- AMP-Activated Protein Kinase31 topic
- Cardiovascular Outcomes31 topic
- Counterfeit Drugs31 topic
- Cyclooxygenase-2 Inhibitors31 topic
- Metformin31 topic
- Prostaglandins31 topic
- Substandard Medicines31 topic
- Type 2 Diabetes31 topic
- PPARs21 topic
- Peroxisome Proliferator-Activated Receptors21 topic
Where does Tjark Reblin work?
Tjark Reblin's main affiliation in the publication record is Eppendorf (Germany), Germany.
How many publications and citations does Tjark Reblin have?
OpenAlex counts 25 works and 1,079 citations for Tjark Reblin, an h-index of 14, ranking #3,331,150 of 7,710,434 researchers worldwide on the quality score.
Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.
Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.
Discussion
Ask a question or share a note about Tjark Reblin. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.